<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02012166</url>
  </required_header>
  <id_info>
    <org_study_id>0893-002</org_study_id>
    <secondary_id>2005-002198-57</secondary_id>
    <nct_id>NCT02012166</nct_id>
  </id_info>
  <brief_title>A Study of MK-0893 on Glucagon-Induced Glycemic Excursion in Healthy Male Participants Following Intravenous Administration of Glucagon, Sandostatine® and Insulin (MK-0893-002)</brief_title>
  <official_title>A Double-Blind, Randomized, Placebo-Controlled, Single-Dose, 3-Period, 4 Treatment Incomplete Crossover Study to Assess the Effects of Single Oral Doses of L-001241689 on Glucagon-Induced Glycemic Excursion in Healthy Male Subjects Following Intravenous Administration of Glucagon, Sandostatine® and Insulin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a study to assess the pharmacokinetics, safety, and tolerability of sequential single
      oral doses of MK-8093 10 mg, 40 mg, 200 mg, or placebo to MK-8093 (Part 1) depending on
      treatment assignment in young healthy male participants. In Part 2 of this study, sequential
      single oral doses of MK-8093 200 mg, 1000 mg or placebo to MK-8093 depending on treatment
      assignment will be evaluated. The primary hypothesis of the study is that at least one dose
      of MK-0893 will produce greater reduction of glucagon-induced glycemia as compared to placebo
      following the infusion of glucagon, Sandostatine®, and basal insulin.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2005</start_date>
  <completion_date type="Actual">December 2005</completion_date>
  <primary_completion_date type="Actual">December 2005</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Post-infusion Incremental Glucose Area Under the Plasma Concentration Versus Time Curve [AUC0-240 min] Study Part 1</measure>
    <time_frame>Up to 76 hours postdose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Post-infusion Incremental Glucose Area Under the Plasma Concentration Versus Time Curve [AUC0-240 min] Study Part 2</measure>
    <time_frame>Up to 124 hours postdose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With An Adverse Event (AE)</measure>
    <time_frame>Up to 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Discontinued Study Treatment Due To AEs</measure>
    <time_frame>Up to 21 days of each treatment period</time_frame>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>MK-0893 40 mg→MK-0893 200 mg→placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In Part 1 of the study, participants receive MK-0893 (10 mg, 40 mg or 200 mg) or placebo on Day 1 of each period, and Sandostatine® (30 ng/kg/min), insulin (0.10 mIU/kg/min), and glucagon (3 ng/kg/min) at 24 and 72 hours post dose. In Part 2 of the study, participants receive MK-0893 (200 mg or 1000 mg) or placebo on Day 1 of each period and Sandostatine®, insulin, and glucagon at 120 hours post dose. There will be at least 21 days between administrations of study drugs.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MK-0893 200 mg→placebo→MK-0893 10 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In Part 1 of the study, participants receive MK-0893 (10 mg, 40 mg or 200 mg) or placebo on Day 1 of each period, and Sandostatine® (30 ng/kg/min), insulin (0.10 mIU/kg/min), and glucagon (3 ng/kg/min) at 24 and 72 hours post dose. In Part 2 of the study, participants receive MK-0893 (200 mg or 1000 mg) or placebo on Day 1 of each period and Sandostatine®, insulin, and glucagon at 120 hours post dose. There will be at least 21 days between administrations of study drugs.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo→MK-0893 10 mg→MK-0893 40 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In Part 1 of the study, participants receive MK-0893 (10 mg, 40 mg or 200 mg) or placebo on Day 1 of each period, and Sandostatine® (30 ng/kg/min), insulin (0.10 mIU/kg/min), and glucagon (3 ng/kg/min) at 24 and 72 hours post dose. In Part 2 of the study, participants receive MK-0893 (200 mg or 1000 mg) or placebo on Day 1 of each period and Sandostatine®, insulin, and glucagon at 120 hours post dose. There will be at least 21 days between administrations of study drugs.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MK-0893 10 mg→MK-0893 40 mg→MK-0893 200 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In Part 1 of the study, participants receive MK-0893 (10 mg, 40 mg or 200 mg) or placebo on Day 1 of each period, and Sandostatine® (30 ng/kg/min), insulin (0.10 mIU/kg/min), and glucagon (3 ng/kg/min) at 24 and 72 hours post dose. In Part 2 of the study, participants receive MK-0893 (200 mg or 1000 mg) or placebo on Day 1 of each period and Sandostatine®, insulin, and glucagon at 120 hours post dose. There will be at least 21 days between administrations of study drugs.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo→MK-0893 1000 mg→MK-0893 200 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In Part 1 of the study, participants receive MK-0893 (10 mg, 40 mg or 200 mg) or placebo on Day 1 of each period, and Sandostatine® (30 ng/kg/min), insulin (0.10 mIU/kg/min), and glucagon (3 ng/kg/min) at 24 and 72 hours post dose. In Part 2 of the study, participants receive MK-0893 (200 mg or 1000 mg) or placebo on Day 1 of each period and Sandostatine®, insulin, and glucagon at 120 hours post dose. There will be at least 21 days between administrations of study drugs.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MK-0893 200 mg→placebo→MK-0893 1000 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In Part 1 of the study, participants receive MK-0893 (10 mg, 40 mg or 200 mg) or placebo on Day 1 of each period, and Sandostatine® (30 ng/kg/min), insulin (0.10 mIU/kg/min), and glucagon (3 ng/kg/min) at 24 and 72 hours post dose. In Part 2 of the study, participants receive MK-0893 (200 mg or 1000 mg) or placebo on Day 1 of each period and Sandostatine®, insulin, and glucagon at 120 hours post dose. There will be at least 21 days between administrations of study drugs.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MK-0893 1000 mg→MK-0893 200 mg→placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In Part 1 of the study, participants receive MK-0893 (10 mg, 40 mg or 200 mg) or placebo on Day 1 of each period, and Sandostatine® (30 ng/kg/min), insulin (0.10 mIU/kg/min), and glucagon (3 ng/kg/min) at 24 and 72 hours post dose. In Part 2 of the study, participants receive MK-0893 (200 mg or 1000 mg) or placebo on Day 1 of each period and Sandostatine®, insulin, and glucagon at 120 hours post dose. There will be at least 21 days between administrations of study drugs.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MK-0893 10 mg</intervention_name>
    <description>MK-0893 10 mg administered orally in 240 mL of water</description>
    <arm_group_label>MK-0893 200 mg→placebo→MK-0893 10 mg</arm_group_label>
    <arm_group_label>Placebo→MK-0893 10 mg→MK-0893 40 mg</arm_group_label>
    <arm_group_label>MK-0893 10 mg→MK-0893 40 mg→MK-0893 200 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MK-0893 40 mg</intervention_name>
    <description>MK-0893 40 mg administered orally in 240 mL of water</description>
    <arm_group_label>MK-0893 40 mg→MK-0893 200 mg→placebo</arm_group_label>
    <arm_group_label>Placebo→MK-0893 10 mg→MK-0893 40 mg</arm_group_label>
    <arm_group_label>MK-0893 10 mg→MK-0893 40 mg→MK-0893 200 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MK-0893 200 mg</intervention_name>
    <description>MK-0893 200 mg administered orally in 240 mL of water</description>
    <arm_group_label>MK-0893 40 mg→MK-0893 200 mg→placebo</arm_group_label>
    <arm_group_label>MK-0893 200 mg→placebo→MK-0893 10 mg</arm_group_label>
    <arm_group_label>MK-0893 10 mg→MK-0893 40 mg→MK-0893 200 mg</arm_group_label>
    <arm_group_label>Placebo→MK-0893 1000 mg→MK-0893 200 mg</arm_group_label>
    <arm_group_label>MK-0893 200 mg→placebo→MK-0893 1000 mg</arm_group_label>
    <arm_group_label>MK-0893 1000 mg→MK-0893 200 mg→placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MK-0893 1000 mg</intervention_name>
    <description>MK-0893 1000 mg administered orally in 240 mL of water</description>
    <arm_group_label>Placebo→MK-0893 1000 mg→MK-0893 200 mg</arm_group_label>
    <arm_group_label>MK-0893 200 mg→placebo→MK-0893 1000 mg</arm_group_label>
    <arm_group_label>MK-0893 1000 mg→MK-0893 200 mg→placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo administered orally in 240 mL of water</description>
    <arm_group_label>MK-0893 40 mg→MK-0893 200 mg→placebo</arm_group_label>
    <arm_group_label>MK-0893 200 mg→placebo→MK-0893 10 mg</arm_group_label>
    <arm_group_label>Placebo→MK-0893 10 mg→MK-0893 40 mg</arm_group_label>
    <arm_group_label>Placebo→MK-0893 1000 mg→MK-0893 200 mg</arm_group_label>
    <arm_group_label>MK-0893 200 mg→placebo→MK-0893 1000 mg</arm_group_label>
    <arm_group_label>MK-0893 1000 mg→MK-0893 200 mg→placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Sandostatine®</intervention_name>
    <description>Sandostatine® is a somatostatin analogue. At 24 and at 72 (Part I) or 120 (Part II) hours postdose, simultaneous infusions of the Sandostatine®, insulin, and glucagon will be administered over a 2-hour period. These compounds are IV compatible and will be combined in one syringe. Intravenous Sandostatine® will be administered at 30 ng/kg/min.</description>
    <arm_group_label>MK-0893 40 mg→MK-0893 200 mg→placebo</arm_group_label>
    <arm_group_label>MK-0893 200 mg→placebo→MK-0893 10 mg</arm_group_label>
    <arm_group_label>Placebo→MK-0893 10 mg→MK-0893 40 mg</arm_group_label>
    <arm_group_label>MK-0893 10 mg→MK-0893 40 mg→MK-0893 200 mg</arm_group_label>
    <arm_group_label>Placebo→MK-0893 1000 mg→MK-0893 200 mg</arm_group_label>
    <arm_group_label>MK-0893 200 mg→placebo→MK-0893 1000 mg</arm_group_label>
    <arm_group_label>MK-0893 1000 mg→MK-0893 200 mg→placebo</arm_group_label>
    <other_name>Octreotide acetate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Insulin</intervention_name>
    <description>At 24 and at 72 (Part I) or 120 (Part II) hours postdose, simultaneous infusions of the Sandostatine®, insulin, and glucagon will be administered over a 2-hour period. These compounds are IV compatible and will be combined in one syringe. Intravenous insulin will be administered at 0.10 milli-international unit (mIU)/kg/min.</description>
    <arm_group_label>MK-0893 40 mg→MK-0893 200 mg→placebo</arm_group_label>
    <arm_group_label>MK-0893 200 mg→placebo→MK-0893 10 mg</arm_group_label>
    <arm_group_label>Placebo→MK-0893 10 mg→MK-0893 40 mg</arm_group_label>
    <arm_group_label>MK-0893 10 mg→MK-0893 40 mg→MK-0893 200 mg</arm_group_label>
    <arm_group_label>Placebo→MK-0893 1000 mg→MK-0893 200 mg</arm_group_label>
    <arm_group_label>MK-0893 200 mg→placebo→MK-0893 1000 mg</arm_group_label>
    <arm_group_label>MK-0893 1000 mg→MK-0893 200 mg→placebo</arm_group_label>
    <other_name>Humuline Regular, Insulin for human injection</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Glucagon</intervention_name>
    <description>At 24 and at 72 (Part I) or 120 (Part II) hours postdose, simultaneous infusions of the Sandostatine®, insulin, and glucagon will be administered over a 2-hour period. These compounds are IV compatible and will be combined in one syringe. Intravenous glucagon will be administered at 3 ng/kg/min.</description>
    <arm_group_label>MK-0893 40 mg→MK-0893 200 mg→placebo</arm_group_label>
    <arm_group_label>MK-0893 200 mg→placebo→MK-0893 10 mg</arm_group_label>
    <arm_group_label>Placebo→MK-0893 10 mg→MK-0893 40 mg</arm_group_label>
    <arm_group_label>MK-0893 10 mg→MK-0893 40 mg→MK-0893 200 mg</arm_group_label>
    <arm_group_label>Placebo→MK-0893 1000 mg→MK-0893 200 mg</arm_group_label>
    <arm_group_label>MK-0893 200 mg→placebo→MK-0893 1000 mg</arm_group_label>
    <arm_group_label>MK-0893 1000 mg→MK-0893 200 mg→placebo</arm_group_label>
    <other_name>Glucagen</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Good health

          -  Body Mass Index of between 18 and 28 kg/m^2, or up to 30 kg/m^2 with approval of
             sponsor

          -  Non-smoker for at least 6 months

          -  Willing to avoid strenuous physical activity

          -  Willing to avoid alcohol, caffeine, and grapefruit juice consumption

        Exclusion Criteria:

          -  History of renal, neurologic, gastrointestinal or respiratory disease or any
             gastrointestinal surgery

          -  History of multiple and/or severe allergies to a prescription, nonprescription or
             investigational drug or food

          -  History of any cardiovascular/cardiac disease

          -  History of any hepatic disease and primary biliary cirrhosis

          -  History of hypoglycemia or glucose intolerance, type 1 diabetes, or type 2 diabetes

          -  Requires or anticipates use of prescription or nonprescription medications, including
             herbal remedies

          -  A user of any illicit drugs or a history of drug or alcohol abuse

          -  Surgery, donated a unit of blood, or participated in another clinical study within 4
             weeks prior to study participation

          -  History of hypersensitivity to insulin, glucagon, or Sandostatine®.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <verification_date>August 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 3, 2013</study_first_submitted>
  <study_first_submitted_qc>December 10, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 16, 2013</study_first_posted>
  <last_update_submitted>August 18, 2015</last_update_submitted>
  <last_update_submitted_qc>August 18, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 19, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diabetes Mellitus</keyword>
  <keyword>Diabetes Mellitus, Type 2</keyword>
  <keyword>Glucose Metabolism Disorders</keyword>
  <keyword>Metabolic Diseases</keyword>
  <keyword>Endocrine System Diseases</keyword>
  <keyword>Therapeutic Uses</keyword>
  <keyword>Pharmacologic Actions</keyword>
  <keyword>Molecular Mechanisms of Pharmacological Action</keyword>
  <keyword>Physiological Effects of Drugs</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Glucagon</mesh_term>
    <mesh_term>Octreotide</mesh_term>
    <mesh_term>Glucagon-Like Peptide 1</mesh_term>
    <mesh_term>Molecular Mechanisms of Pharmacological Action</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

